In addition to its oncolytic effect, T-VEC is also designed to elicit anti-tumor response by releasing tumor-associated antigens and providing cytokine stimuli via the local production of human granulocyte macrophage colony-stimulating factor (GM-CSF) encoded by the virus [6]. This evidence concerns the gene CSF2 and neoplasm.